Your session is about to expire
← Back to Search
Antiparasitic
Role of Ivermectin Nanosuspension as Nasal Spray in Treatment of Persistant Post covid19 Anosmia
Phase 2 & 3
Waitlist Available
Research Sponsored by South Valley University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up within 14 days after enrollemen ]
Awards & highlights
All Individual Drugs Already Approved
Summary
ivermectin is FDA approaved antiparasitic drug which is also claimed to be having potent in vitro antiviral effect,so we are tryying to study itsovid19 anosmia effect upon releiving post covid19 anosmia
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ within 14 days after enrollemen ]
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~within 14 days after enrollemen ]
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
regaining of smell
Awards & Highlights
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Trial Design
2Treatment groups
Active Control
Placebo Group
Group I: intranasal Ivermectin groupActive Control1 Intervention
49 pateints with anosmia received ivermectin nanosuspension nasal spray
Group II: saline nasal sprayPlacebo Group1 Intervention
47 pateints with anosmia received saline nasal spray
Find a Location
Who is running the clinical trial?
South Valley UniversityLead Sponsor
115 Previous Clinical Trials
13,981 Total Patients Enrolled